Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study

View Full Paper
Ask AI
Bookmark
Share

Authors

OBOsama BataynehAPAnsy PatelMNMichel R. Nasr

Discussion

Loading...

Member takes

Overview

Analysis reveals co-mutations of DNMT3A and NPM1 in Acute Myeloid Leukemia cases, suggesting unique genomic profiles and treatment targets.

Key Points

  • Co-mutations in DNMT3A and NPM1 occur in 7.7% of Acute Myeloid Leukemia cases, influencing treatment strategies.
  • The co-mutated group had a unique genomic profile compared to DNMT3A/NPM1 wild type, altering treatment approaches.
  • Comprehensive genomic profiling used on 3,165 AML cases showed significant differences in mutation patterns.
  • Understanding genomic alterations in these co-mutated cases may enable targeted therapy advancements.

Cite This Study

Batayneh et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a0https://doi.org/10.1182/blood-2025-1722
View Full Paper
Ask AI
Bookmark
Share